NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna® Breast Cancer Prognostic Gene Signature Assay for assessing a woman’s 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.
NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay
Today, we’ve launched an updated BiomarkerCommons.org website. We’ve kept the clean page style and introduce larger, easier-to-read fonts and a new layout optimized for all your mobile devices.
Biomarker Commons launched three-and-a-half years ago with an ambitious goal: curate the growing biomarker industry and track the discovery, development and use of biomarkers. Our business plan was simple: support the site with advertising revenue. Not surprisingly, given the changes to the media industry over the last few years, that plan hasn’t worked out.
Biomarker Commons launched just over three years ago with the goal of aggregating the latest biomarker and personalized medicine news.
Now, we really need your feedback. We’ve got 8 simple questions that should take you less than 5 minutes to complete. Please let us know how we’ve been doing and what we can do to improve our service.